Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Evaluating serum free light chain ratio as a biomarker for progression to multiple myeloma

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, discusses the results and implications of a retrospective study assessing the risk of progression to multiple myeloma in patients with smoldering multiple myeloma with a serum free light chain (FLC) ratio ≥100. The study found that while this threshold is associated with a high risk of progression, with a median time to progression of 31 months, only a minority of patients progressed in the first six months and less than 50% progressed within a year, and select patients never progressed to multiple myeloma. These results suggest that treatment should not be initiated in all patients with a FLC ratio ≥100, and other high-risk features should be considered when making the decision to start therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research Funding: Amgen, Takeda, Sanofi; Speaker’s Bureau, Advisory Boards: Amgen, Takeda, Celgene-BMS, Janssen, Sanofi, Seattle Genetics